Eleventh Circuit Rejects the Strength of a Patent as a Criterion for the Legality of Reverse-Payment Settlements

Jodi Lucena-Pichardo, William Rooney, Jun 27, 2012

The Eleventh Circuit’s recent decision in Federal Trade Commission v. Watson Pharmaceuticals, Inc. (the “AndroGel” decision) addresses the latest challenge to reverse-payment settlements. The Eleventh Circuit rejected the Federal Trade Commission’s position that the lawfulness of a reverse-payment settlement depends on the perceived strength or weakness of the patent and concluded that a patent, unless previously invalidated, should be given its full exclusionary scope.

Links to Full Content

 

RECOMMENDED FOR YOU
 


More Articles More Articles More Articles More Articles More Articles More Articles More Articles More Articles